Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Genespire logo — Biotechnology company focused on developing transformative g...

Genespire

Biotechnology company focused on developing transformative gene therapies for patients affected by genetic diseases

Founded 2020 Italy Italy 17 employees Series B Total: $62.60M Biotechnology, Life Sciences

General Information

Company Name Genespire
Founded Year 2020
Location Italy Italy
Employees 17
Industries Biotechnology, Life Sciences
Funding Stage Series B
Business Model B2B, B2B2C, B2B2B
Revenue Model Product Sales, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Genespire. To contact Genespire, visit genespire.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Genespire compare?

A PDF of Genespire and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Genespire soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 27, 2026

Genespire's CEO, Dr Lucia Faccio, will speak on a panel at BIO Europe in Cologne.

Genespire a competitor of yours? Have our desk watch it

About Genespire

Genespire is a promising player in the biotechnology sector, specializing in developing transformative gene therapies to tackle complex genetic diseases. The company primarily addresses primary immunodeficiencies and inherited metabolic diseases, aiming for durable solutions that significantly improve patient outcomes. This Milan-based company was founded in March 2020 by experts like Prof. Luigi Naldini and Dr. Alessio Cantore, along with entities like Fondazione Telethon and Ospedale San Raffaele.

As a spin-off from the renowned SR-Tiget, Genespire benefits from cutting-edge research in cell and gene therapy. Its potential was recently acknowledged in a substantial €46.60M Series B investment in September 2024, led by experienced investors including Sofinnova Partners, Indaco Venture Partners, XGEN Venture, and CDP Venture Capital. This fresh capital is expected to accelerate its research and development endeavors, solidifying its standing in the ever-evolving life sciences landscape.

Business keywords: Gene Therapy, Primary Immunodeficiencies, Inherited Metabolic Diseases, Durable Therapies, Transformative Therapies, Genetic Diseases, Cell Therapy, SR-Tiget Spin-off, Research Institute Collaboration, Healthcare Innovation, Therapeutic Development, Medical Research, Biotech Start-up, Sofinnova Partners-Backed

Services & Products

development of gene therapies
research and development in gene therapy
immune-shielded lentiviral vector production

Target Customers

children with genetic diseases healthcare providers biopharmaceutical partners

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B €46.60M 4
Sofinnova Partners Indaco Venture Partners XGEN Venture
Sofinnova Partners, Indaco Venture Partners +2
24 Sep 2024
Series A €16.00M 1
Sofinnova Partners
Sofinnova Partners
29 Apr 2020

Genespire Alternatives & Competitors

View All Alternatives
Genespire vs
Basilard BioTech, Inc.
Basilard BioTech, Inc. United States

Nanomechanical Gene Delivery to Transform the Engineering of Cell Based Therapies

Seed
5 employees
Biopharma, Biotechnology
Genespire vs
Taysha Gene Therapies
Taysha Gene Therapies United States

Taysha Gene Therapies is focused on advancing AAV-based gene therapies for severe monogenic diseases...

IPO
134 employees
Biotechnology, Life Sciences
Genespire vs
InVenis Biotherapies
InVenis Biotherapies France

Platelet-derived Regenerative Therapy for CNS Disorders

Non Equity Assistance
2 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Genespire

Biotechnology company focused on developing transformative gene therapies for patients affected by genetic diseases
Genespire was founded in 2020.
Genespire is headquartered in Italy.
Genespire operates in Biotechnology and Life Sciences. Its work centres on Gene Therapy, Primary Immunodeficiencies, Inherited Metabolic Diseases and Durable Therapies. Its customers include children with genetic diseases, healthcare providers and biopharmaceutical partners.
Genespire has a B2B, B2B2C and B2B2B business model. Its revenue comes from Product Sales, Licensing and Performance Based.
Genespire has approximately 17 employees.
Genespire has completed 2 funding rounds, raising a total of $62.60M. The latest funding stage is Series B.
Genespire offers: development of gene therapies, research and development in gene therapy, immune-shielded lentiviral vector production.
Top alternatives and competitors to Genespire include Basilard BioTech, Inc., Taysha Gene Therapies, InVenis Biotherapies, BridgeBio, Evommune. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Genespire and Basilard BioTech, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Genespire, https://bouncewatch.com/company/genespire, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout